2.1. Design
neurological diseases, infectious
PULMONARY EMBOLISM, NEUROLOGICAL DISEASE, COAGULATION DISORDERS, DEEP VEIN THROMBOSIS, CORONARY DISEASES
We conducted a randomized controlled trial of patients following a primary total knee replacement between October 2020 and August 2021 in our center. We excluded from our study patients with revisions and cases requiring a greater constraint than a posterior stabilized TKA (constrained or hinged knee). We also excluded patients with coronary diseases, neurological diseases, infectious conditions, coagulation disorders or a history of deep vein thrombosis or pulmonary embolism. Inclusion criteria consisted of patients aged between 50–80 years and with BMI < 45 kg/m